Topical Drug Delivery Market – Global Trends & Key Players

Summary

• High prevalence of skin diseases.
• High incidence of burn injuries.
• Growing prevalence of diabetes.
• Rising prevalence of eye diseases.

Research Methodologies Followed for the Study of Topical Drug Delivery Market:

Secondary Research:

This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and company house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global topical drug delivery market.

It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research:

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, manufacturing managers, and related key executives from various key companies and organizations operating in the global topical drug delivery market. The primary sources from the demand side include purchase and sales managers, research organizations, and pharmaceutical and biotechnology companies.

Key Players:

The topical drug delivery market is consolidated at the top with a large number of leading market players based in developed countries. The prominent players operating in this market include Johnson & Johnson (US), Nestlé SA (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline (UK), Bausch Health Companies (Canada), Merck & Co (US), Bayer AG (Germany), Hisamitsu Pharmaceutical (Japan), Glenmark Pharmaceuticals (India), Cipla Ltd (India), Crescita Therapeutics Inc. (Canada), Mylan (US), Encore Dermatology, Inc. (US), LEO Pharma (Denmark), Almirall, S.A (Spain), Aclaris Therapeutics, Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Teligent Pharma (US), Perrigo Pharma (US), Allergan (Ireland), Biofrontera, Inc. (US), Crown Laboratories Inc. (US), Akorn Inc. (US), Ingenus Pharmaceuticals (US), and Sun Pharmaceuticals (India).

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124871717

What the Market Looks Like?

The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4% during the forecast period.

Janssen Global Services LLC, a subsidiary of Johnson & Johnson provides medicines for an array of health concerns in several therapeutic areas, such as general medicine, mental health, neurology, pain management, and women’s health. To maintain its leading position in the market, the company focuses on acquisitions. For instance, in January 2018, Johnson & Johnson entered into a definitive agreement to acquire Ci:z Holdings Co., Ltd. (Japan). The acquisition gives J&J access to Ci:z Holdings’ line of topical skin health products, helping it diversify its drug portfolio in Japan and other Asia Pacific countries.

Galderma, a subsidiary of Nestlé, is a provider of dermatology solutions and aesthetic and corrective products internationally. The company offers a broad portfolio of topical products, which include drugs, medical dermatology solutions, and therapeutic skin care products that are used in the treatment of hair, nail, and skin diseases. The company focuses on product approvals, product launches, and expansions to maintain its leading position in the topical drug delivery market.

Novartis manufactures healthcare and pharmaceutical products. It operates in three segments—Pharmaceuticals, Alcon (Eye Care), and Sandoz (Generics). The company has a broad range of access-to-medicine programs, which include drug donations, social business initiatives, and patient assistance programs.

Novartis has a presence in over 155 countries, including the US, Europe, Asia, Africa, and Latin America. In order to maintain its leading position, the company significantly invests in R&D activities, which helps it to develop and launch new and advanced products. In 2018, the company invested 12.6% of its total revenue on R&D activities. A diversified product portfolio, wide geographical reach, and constant focus on R&D have enabled the company to create a strong foothold in the topical drug delivery market.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=124871717